Vaccine innovation spurred by the long wait for an Ebola virus vaccine
Item
Click for External Resource*
Click to read full article*
*The link above may share a zip file (.zip) hosted on repository.netecweb.org. Zip files will download automatically.
*All other links are external and will open in a new window. If you click an external link, you are leaving the NETEC site, and we do not maintain, review, or endorse these materials. See our terms of use.
Item Type
PublicationTerms of Use
By accessing these materials you are agreeing to our terms of use, which may be found here: Terms of Use.
Example only: NETEC provides this item for reference purposes but does not endorse its content. Newer versions may be in place at the providing institution.
Title
Vaccine innovation spurred by the long wait for an Ebola virus vaccine
Subject
Description
The 2013–16 Ebola virus outbreak—the largest ever recorded—substantially hastened the development of an Ebola virus vaccine. Before this outbreak, the safety and immunogenicity of only two Ebola virus vaccine candidates (a DNA-based vaccine and a recombinant adenovirus [rAd] serotype 5-based vaccine) had been evaluated in phase 1 clinical trials.
Date
2020-11-17
Type
Citation
Fausther-Bovendo, Hugues, and Gary Kobinger. 2020. "Vaccine innovation spurred by the long wait for an Ebola virus vaccine." The Lancet Infectious Diseases.
Accessibility
Free online on Lancet site.
Was this resource helpful?